BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain four FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
Current indications include major depressive disorder, obsessive-compulsive disorder, smoking addiction, and anxious depression. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA, Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit the news page.
A career with BrainsWay is more than just a job. It’s personal. As a leader in non-invasive brain stimulation we’re deeply committed to help patients who suffer from brain disorders. If you’re a natural problem-solver with the imagination, courage and spirit to make a meaningful difference, BrainsWay is where you want to build your career.
See all the latest news, events and in the media BrainsWay has to offer, and everything in-between.
News November 17, 2021
Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS™ System...
News November 3, 2021
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...
News October 12, 2021
Zafiris Daskalakis, MD, PhD to Bring Extensive Research and Clinical Expertise to Assist in Guiding Growth...
